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Abstract 22 
Pseudomonas aeruginosa is the most common bacterial pathogen infecting the lungs of cystic 23 
fibrosis (CF) patients. The transmissible Liverpool Epidemic Strain (LES) harbours multiple 24 
inducible prophages (LES2; LES3; LES4; LES5; and LES6), some of which are known 25 
to confer a competitive advantage in an in vivo rat model of chronic lung infection.  We used 26 
quantitative PCR (Q-PCR) to measure the density and dynamics of all five LES phages in the 27 
sputa of 10 LES-infected CF patients over a period of two years. In all patients, the densities of 28 
free LES-phages were positively correlated with the densities of P. aeruginosa, and total free phage 29 
densities consistently exceeded bacterial host densities 10 - 100 fold. Further, we observed a 30 
negative correlation between the phage-to-bacterium ratio and bacterial density, suggesting a role 31 
for lysis by temperate phages in regulation of the bacterial population densities. In 9/10 patients, 32 
LES2 and LES4 were the most abundant free phages, which reflects the differential in vitro 33 
induction properties of the phages. These data indicate that temperate phages of P. aeruginosa 34 
retain lytic activity after prolonged periods of chronic infection in the CF lung, and suggest that 35 
temperate phage lysis may contribute to regulation of P. aeruginosa density in vivo.   36 
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Original Article 42 
Introduction 43 
Cystic Fibrosis (CF) patients are subject to life-long chronic respiratory infections, most 44 
commonly with the bacterium Pseudomonas aeruginosa. Periodic exacerbation of symptoms occurs 45 
throughout the lifetime of CF patients leading to progressive deterioration of lung function. 46 
Phage particles have been detected in the sputa of CF patients (Fothergill et al 2011, Ojeniyi et al 47 
1991). Metagenomic analysis of CF sputa has identified >450 viral genotypes, while most viruses 48 
were unknown, of those that could be identified viruses the majority were infective against CF 49 
pathogens, including many Pseudomonas phages (Lim et al 2014). More generally, phages, 50 
outnumber eukaryotic viruses both in abundance and diversity in the human virome (Reyes et al 51 
2012), and  are known to be present at various body sites including the gastrointestinal (Breitbart 52 
et al 2003, Kim et al 2011) and the respiratory tracts (Willner et al 2009). However, the in vivo 53 
ecological dynamics of temperate bacteriophages and their role during bacterial infections remain 54 
largely unknown.  55 
Upon infection of a bacterial cell, a temperate phage can either complete the lytic cycle or 56 
integrate into the bacterial chromosome as a prophage, which may subsequently be induced to 57 
enter the lytic cycle by a range of bacterial or environmental cues (Ghosh et al 2009, Little 2005). 58 
Because lysis is obviously detrimental to the individual host bacterium it is often assumed that 59 
integrated prophages will eventually lose their lytic activity, becoming cryptic. While the selective 60 
forces and mechanisms driving this remain poorly understood, inactive prophage remnants have 61 
been detected in many bacterial species, and are thought to result from an ongoing process of 62 
phage decay (Brussow et al 2004). This could be due to the accumulation of mutations for 63 
example, to inactivate phage N-anti-terminator genes (Desiere et al 2001)  and portal protein 64 
genes (Lawrence et al 2001), preventing completion of the replicative cycle. By contrast, lytic 65 
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activity may be retained if it enhances bacterial population fitness for example by acting as an 66 
anti-competitor strategy or through the release of virulence-related toxins upon lysis (Brown et al 67 
2006, Brussow et al 2004, Willner et al 2009). Over longer evolutionary timescales, the 68 
domestication of prophages is thought to be an important process in the evolution of bacteria, 69 
leading to the origin of a number of phage-derived traits (e.g., bacteriocins, killer particles 70 
etc.;(Bobay et al 2014)) 71 
The P. aeruginosa Liverpool Epidemic Strain (LES) exhibits increased antibiotic resistance 72 
levels compared to other P. aeruginosa isolates from CF patients (Ashish et al 2012) and is 73 
widespread across the UK (Martin et al 2013). Patients infected with this strain have been shown 74 
to suffer greater morbidity than those infected with other strains (Al-Aloul et al 2004, Fothergill 75 
et al 2012). The P. aeruginosa LESB58 genome contains 5 inducible prophages and transposon 76 
mutagenesis of this isolate identified several mutations in prophages encoding LES2, LES3 77 
and LES5 that reduced bacterial competitiveness in a rat model of chronic lung infection 78 
(Winstanley et al 2009), suggesting that the phages play a key role in the infection process. We 79 
have previously characterised the infection properties of several LES phages in vitro. Induction 80 
experiments demonstrated that free LES2 was produced more rapidly and in higher numbers 81 
than LES3 and LES4 in response to norfloxacin. Each phage was shown to exhibit a different 82 
immunity profile and was able to infect a range of susceptible P. aeruginosa hosts via the type IV 83 
pili (James et al 2012). Due to a lack of suitable acceptor strains, we have thus far been unable to 84 
isolate and purify LES5 and LES6. 85 
In this study, we used culture-independent quantitative PCR (Q-PCR) to follow the 86 
ecological dynamics of all five active LES phage populations in 188 expectorated sputum 87 
samples from ten long-term LES-infected patients over a period of 28 months. To our 88 
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knowledge this represents the first longitudinal study of a bacterial pathogen and its temperate 89 
phages in a human chronic infection. 90 
 91 
Materials and Methods 92 
 93 
Patients and Samples 94 
188 sputum samples were collected from 10 LES-infected CF patients, for diagnostic purposes, 95 
over a period of more than two years (January 2009 to May 2011). The details of each patient 96 
and the sampling rationale have been described previously (Fothergill et al 2010, Mowat et al 97 
2011a).  All patients had long-term LES infections (duration at beginning of the study ranged 98 
from >5-to- >10 years). Table 1 and Figure S1 describe the number and dates of acquired 99 
samples from each patient that were analysed for density of LES bacteria and LES phages. 98 100 
samples were collected during routine visits when each patient was well (stable) and 90 samples 101 
were collected during periods of acute exacerbated symptoms of respiratory infection (acute). 102 
Sputa obtained during exacerbation periods included samples taken before and during aggressive 103 
intravenous antibiotic treatment (Table 1, Figure S1). The criteria for diagnosing exacerbations 104 
were physician-based and have been described previously (Mowat et al 2011a). Briefly, patients 105 
were considered to be undergoing an exacerbation if they showed signs of reduced lung capacity, 106 
increased sputum production and discoloration, increased temperature, cough, dyspnea and 107 
malaise (Goss and Burns 2007). Where known, antibiotics administered to patients during the 108 
study period are listed in Table 1.  However, detailed information of the antibiotics administered 109 
during each exacerbation is very incomplete. Thus we were unable to fully assess the effect of 110 
different antibiotics on phage induction in vivo. This study was approved by the local research 111 
ethics committee (REC reference 08/H1006/47). 112 
 113 
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Detection of viable phage particles by plaque assay 114 
We were unable to accurately determine phage densities by culture-dependent techniques for 115 
several reasons: (a) we lacked acceptor strains for LES5 and LES6; (b) culturable phages were 116 
indistinguishable by plaque morphology; and (c) sputum samples were routinely frozen upon 117 
collection which reduced phage viability. However, to confirm the presence of viable phage 118 
particles in sputum samples, we quantified the density of culturable phages in ten sputum 119 
samples from 3 LES-infected patients (CF3, CF4 and CF7). Sputum samples (50 µl) were treated 120 
with sputasol (200 µl) and incubated at 37 ºC for 1 h, with shaking at 200 r.p.m. Treated samples 121 
were diluted with sterile phosphate buffered saline.  A rifampicin-resistant mutant (PAO1-rif) 122 
was created by successive passage in increasing rifampicin concentrations (method described 123 
by(James et al 2001)). This enabled enumeration of active phages capable of infecting PAO1 124 
directly from un-filtered sputum. Briefly, mid-exponential phase PAO1-rif (OD600 0.5; 100µl) was 125 
added as an indicator host to treated sputum samples (400 µl). Rifampin (300 mg ml-1) was 126 
incorporated in the soft agar overlay (5 ml; 0.4 % [w/v] LB agar) to select for the indicator host 127 
and incubated overnight at 37°C before the plaques were counted. This method only provides 128 
confirmation that active P. aeruginosa phages are present in the sputa. It does not accurately 129 
reflect abundance and does not discriminate between phages. 130 
 131 
Real-time Q-PCR 132 
To overcome the limitations of culture-dependent methods, we have developed and validated a 133 
simple quantitative (Q)-PCR protocol to measure the density of each individual LES phage 134 
(James et al 2012). Each sputum sample was treated with an equal volume of Sputasol (Oxoid, 135 
Basingstoke) and incubated at 37oC for 30 min, with shaking at 200 r.p.m.  DNA was prepared 136 
from each treated sputum sample (400 l) using the “Bacterial and Virus DNA extraction kit” 137 
(Qiagen, Valencia, CA, USA) and the automated QIAsymphony machine (QIAGEN; pathogen 138 
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complex 200 protocol). The protocol yielded 0.3 – 0.9 µg µl-1 DNA. Each sample was diluted 139 
1:100 with sterile distilled H2O. The number of DNA copies of each LES phage in sputum and 140 
bacterial culture samples was quantified from extracted DNA. The number of specific copies 141 
detected for each phage was compared to a concentration gradient of known standards (James et 142 
al 2012). For each LES phage (LES2 - LES6), two specific primer sets were used to quantify i) 143 
prophage and ii) total copies (10 primer sets in total). Differentiation between total phage and 144 
prophage copies, allowed free-phage densities to be calculated as the difference between these 145 
values as previously described (James et al 2012).   Bacterial host density was quantified using 146 
primers specific for P. aeruginosa (PS21-6F1/PS21-6R1 and gyrPA-F1/gyrPA-R1) (Fothergill et al 147 
2013). All primer sequences and targets are listed in Table S1.  148 
Q-PCR reactions (25 µl) contained 1 µM each primer pair and 1X Rotorgene-SYBR 149 
green super-mix (Qiagen). All primer sets were used with the same cycling conditions: 95 °C for 150 
10 min; followed by 40 cycles of 95 °C for 10 s, 60 °C for  15 s, and 72 °C for 20 s. Phage DNA 151 
copy numbers were quantified from DNA samples (1 μl) in triplicate using a Rotorgene cycler 152 
(Qiagen). Q-PCR data were analyzed using Rotorgene Q series software 1.7 (Qiagen).  153 
 154 
Sputasol induction experiments 155 
To test for any potential induction properties of sputasol, DNA was extracted from 156 
LESB58 cultures grown to mid-exponential phase in Luria broth (LB) (James et al 2012) treated 157 
(in triplicate) with an equal volume of sputasol or LB for 30 min. DNA was prepared from each 158 
culture using a DNA mini kit (Qiagen) and phage densities estimated by Q-PCR as described for 159 
the sputum samples. No effect of sputasol on phage induction was observed (Figure S2). 160 
 161 
Statistical analysis 162 
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To model phage densities (or phage-to-bacterium ratios), we fitted linear mixed effects 163 
models with Maximum Likelihood using the R package nlme (Pinheiro and Bates 2000) with and 164 
without temporal autocorrelated errors (an ARMA(1) model). Models with temporal 165 
autocorrelated errors were significant improvements over those without, and therefore we 166 
present only these models below. We included a random effect for patient ID and fixed effects 167 
for time, exacerbation, bacterial load and the interaction between bacterial load and exacerbation. 168 
We compared full models with and without temporally autocorrelated errors using a Likelihood 169 
Ratio Test, and then used a backwards stepwise process to remove non-significant fixed effects 170 
until the minimum adequate model was identified. Models analysing normalised variables gave 171 
similar results to those analysing non-normalised data and are presented in the supplementary 172 
information (Table S2a).   173 
 174 
Results 175 
Dynamics of total free-phage abundance 176 
Plaque-assays confirmed the presence of viable particles of the subset of culturable 177 
phages in all sputum samples that were tested (range 1.25 x 102 – 1.39 x 104 p. f. u. ml-1). Free-178 
LES phage DNA was detected in all patient sputa (9.35 x 104 – 5.54 x 109 copies per µl) and, in 179 
general, total free-phage density (i.e. the sum of all the free LES phages present in the sample) 180 
exceeded that of P. aeruginosa within each sample (mean range 11-fold to 90-fold) (Figure 1 and 181 
Table S3). We observed a positive linear relationship between total free-phage density and 182 
bacterial density (Figure 2a & Table S2b; bacterial coefficient 0.607 +- 0.054, LRT = 85.9, d.f. = 183 
1, p < 0.001), consistent with on-going lytic activity by the temperate phages, but no effect of 184 
time or exacerbations on total free-phage densities. Further, we observed a negative linear 185 
relationship between the phage-to-bacterium ratio and bacterial density (Figure 2b & Table S2c 186 
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bacterial coefficient -3.206+- 0.484, LRT = 108.4, d.f. = 1, p < 0.001), suggesting a role for 187 
phage lysis in regulation of bacterial densities.  Time and exacerbations had no significant effect 188 
on phage-to-bacterium ratios. It is perhaps surprising that exacerbations were not associated with 189 
either a change in phage densities or a change in the phage-to-bacterium ratio (Figure 3), given 190 
that these episodes are associated with the administration of high-dose intravenous antibiotics. 191 
However, it should be noted that these patients were all subject to variable cocktails of 192 
antibiotics over several years irrespective of exacerbations (Table 1). Moreover, clinical data on 193 
antibiotic use in these patients was too incomplete to be used in analyses, and therefore effects 194 
of particular antibiotics on phage dynamics may have been missed. 195 
 196 
Abundance heirarchy among individual phages within lungs 197 
Next, we considered each phage individually, observing a general hierarchy of free-phage 198 
densities, though the precise patterns were clearly influenced by the fact that the LES 199 
populations for each patient did not all share the same prophage complement (Table 1). Figure 4 200 
illustrates the free-phage densities of individual LES phages for each of the patients. In the 201 
majority of patients (CF2-CF9) similar free-phage dynamics were observed in that the density of 202 
free LESφ2 was consistently higher than that of the other LES phages, closely followed by 203 
LES4 (Figure 4).    A positive correlation was observed between LESφ2 and LESφ4 densities in 204 
these patients (Table S4). The dynamics observed in samples from patient CF10 (Figure 3) 205 
exhibited a change in the hierarchy of free phage, with considerably higher free LES4 densities 206 
observed. Despite consistent carriage of LES prophage 3, very little free LESφ3 was detected in 207 
patients CF2 - CF10. However, higher levels of free LESφ3 (3.29 x 107 l-1) were observed in all 208 
sputa from patient CF1 (Figure 4), whose P. aeruginosa were the only populations not to carry 209 
prophage 2 (Table 1). We showed previously that LES populations exhibit genotypic diversity, 210 
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including variation in carriage of LES prophages. In particular, the carriage of LES prophage 5 211 
was not consistent in all individuals of a given LES population (Fothergill, et al., 2010). In this 212 
study,   prophage 5 was intermittently detectable in the sputum from patients 7 (up to 105 copies 213 
µl-1) and 10 (102 – 104 copies µl-1). This explains the low density of free LESφ5 in these patients. 214 
Free copies of LESφ6 were not detected in the majority of sputum samples. Where free copies 215 
were detected, the density was lower than the host bacterial load (6.7 x 103 – 1 x 107 copies µl-1). 216 
 217 
Discussion 218 
The levels of free LES phages detected in all patients throughout this study suggest an active 219 
lytic cycle that may be promoted by the presence of H2O2 or DNA damaging antibiotics in the 220 
CF lung (Fothergill et al 2011, McGrath et al 1999). Surprisingly, we observed no effect of 221 
patient exacerbation on total free-phage density, although this is consistent with previous studies 222 
showing that neither fluctuations in P. aeruginosa populations (Mowat et al 2011a), nor in the 223 
wider bacterial population (Fodor et al 2012), show any relationship with the exacerbation period 224 
in chronically infected patients, despite the use of high level intravenous antibiotic therapy. It is 225 
known that particular antibiotics can induce phage lysis, and it is possible that different 226 
antibiotics regimes may have influenced differential induction of phages between patients.  227 
Indeed, we have shown previously that LES induction varies in response to different antibiotics 228 
(Fothergill et al 2011).   Unfortunately, because records of antibiotic treatments for these patients 229 
were very incomplete, we were unable to explicitly test for effects of particular antibiotics in this 230 
study. This would in any case be difficult because of the extensive and varied use of antibiotics in 231 
this group of patients (Table 1), which was not restricted to periods of exacerbation.  232 
Our data do however suggest that on-going phage lysis may play a role in regulating 233 
bacterial density in the CF lung. Treatments which induced the lytic cycle of temperate phages 234 
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could therefore offer a promising alternative or addition to standard antibiotic therapies which in 235 
themselves often do not successfully reduce P. aeruginosa densities in long-term chronically 236 
infected patients (Foweraker 2009, Mowat et al 2011b). Several studies have demonstrated 237 
effective phage-antibiotic synergism in the reduction of bacterial numbers in vitro and in vivo 238 
(Comeau et al 2007, Hagens et al 2006, Knezevic et al 2013). However, this strategy would need 239 
to be considered with caution. Antibiotic therapies that induce stx phages of Shiga-toxigenic E. 240 
coli have been shown to increase expression of shiga toxin genes that are encoded in the late 241 
region of the phage genome and thus increase cytotoxic damage and exacerbate symptoms 242 
(Matsushiro et al 1999). Although we have not identified any obvious virulence factors encoded 243 
in the late gene region of the LES phages (Winstanley, et al., 2009, James, et al., 2012), we cannot 244 
ignore the possibility that the lytic cycle might induce upregulation of virulence genes. 245 
We demonstrate here that LES2 was the most abundant free phage in 9-out-of-10 LES-246 
infected patients. The hierarchy of free LES phage in patient sputa was also observed in our 247 
previous studies of LES phage induction in in vitro bacterial cultures (James et al 2012). This 248 
suggests therefore that LES2 is generally more readily induced or exhibits a more efficient lytic 249 
cycle than the other phages both in vitro and in vivo. In the sputa of patient CF1, who was infected 250 
by a LES that lacked prophage 2, LES3 reached far higher abundances than observed in other 251 
patients, suggesting potential suppression of LES3 lysis by LES2 in vivo. In accordance with 252 
our previous in vitro observations of co-induction of lysis by prophages, we observed a degree of 253 
synchronisation of free-phage dynamics in vivo, suggesting that the phages may be responding to 254 
shared signals, which could include a wide variety of human host, bacterial and environmental 255 
triggers(Little 2005). It is exceptionally difficult to disentangle to drivers of microbial dynamics in 256 
vivo due to the complexity of host microenvironments; future studies using laboratory models of 257 
the infection environment alowing the constituent drivers to be decomposed will be necessary to 258 
elucidate this (Fothergill et al 2014, Wright et al 2013). 259 
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The long-term maintenance of intact, active temperate phages in the LES genome 260 
despite substantial cell lysis suggests some selective or competitive advantage in vivo, consistent 261 
with previous work highlighting a loss of competitiveness observed following the introduction of 262 
mutations to some LES prophage regions (Winstanley et al 2009).  One possibility is that free-263 
phage particles produced by a subpopulation of LES could kill competing bacteria (Brown et al 264 
2006). Indeed, LESφ2, LESφ3 and LESφ4 are capable of infecting and lysing other clinical P. 265 
aeruginosa isolates (James et al 2012).  Thus frequent induction of the lytic cycle may enhance the 266 
competitive ability of LES by promoting superinfection, which has been observed clinically  267 
(McCallum et al 2001), and preventing invasion of the lung by other strains of P. aeruginosa. 268 
Alternatively the prophages may contain accessory genes that contribute directly to LES fitness 269 
in the CF lung, which are only expressed during the lytic cycle, as observed for other pathogens 270 
(Wagner et al 2001). 271 
Little is known about the consequences for the human host of the presence of large 272 
numbers of phage in the lung.  However, high titre phage preparations have recently been found 273 
to interact with the immune system in vivo (Letkiewicz et al 2010). It has also been suggested that, 274 
following adherence to mucous, some phages may act as a form of innate host immunity 275 
enhancing host defences against bacterial pathogens (Barr et al 2013).  Our findings of high free-276 
phage abundances in CF lungs highlight the urgent need for research into the interaction of 277 
phages with host immunity, particularly in CF where dysfunctional immune responses contribute 278 
to pathological processes.  279 
 280 
Supplementary information is available on The ISME journal website 281 
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Figure Legends 430 
Figure 1: Longitudinal dynamics of total free-phage density and P. aeruginosa density 431 
in ten CF patients 432 
Q-PCR assays were used to enumerate free LES phage (dotted line) and P. aeruginosa (solid 433 
line) densities from the sputa of 10 LES-infected CF patients (CF1-CF5 left to right top row, 434 
and CF6-CF10 left to right bottom row) over a two year period. Samples were obtained from 435 
patients both during stable periods (black symbols) and during exacerbation of symptoms 436 
17 
 
(red symbols). The dotted line represents the mean values of all free LES phages (2,3,4,5 and 437 
6) for each patient. The density of free-phage copies of each LES phage was calculated by 438 
subtracting prophage copies from total phage copies in each case.  439 
Figure 2: Relationships of phage density and phage-to-bacterium ratio with bacterial 440 
density. 441 
Datapoints represent sputum samples; patient identity is indicated by colour (see visual key 442 
for details); regression lines indicate significant relationships between variables. Panel A 443 
(upper) shows the positive relationship between log10 phage density and log10 bacterial 444 
density; panel B (lower) shows the negative relationship between phage-to-bacterium ratio 445 
and log10 bacterial density. 446 
 447 
Figure 3: Phage density and phage-to-bacterium ratio are not affected by exacerbations  448 
Outlier box-plots display phage density (upper panel) or phage-to-bacterium ratio (lower 449 
panel) in sputa from patients during stable periods (black) and exacerbations (red).  450 
 451 
Figure 4: Densities of individual LES phage types in patient sputa exhibit hierarchical 452 
trends. 453 
The free-phage densities, calculated for each individual LES phage in the ten CF patients 454 
analysed (CF1-CF5 left to right top row, and CF6-CF10 left to right bottom row).  Each line 455 
represents one LES phage type; LESφ2 (blue); LESφ3 (cyan); LES φ4 (pink); LES φ5 456 
(green); LES φ6 (orange); P. aeruginosa (black circles). All Q-PCR assays were performed 457 
in triplicate and mean values are presented. The density of free-phage copies of each LES 458 
phage was calculated by subtracting prophage copies from total phage copies in each case. 459 
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 Table 1: Patient LES-phage complement and sputum sample summary 
Patient complement Total Stable Exacerbation Antibiotics 
CF1 3, 4, 6 17 14 3 TOB (N), AZT (O) 
CF2 2, 3, 4, 6 11 9 2 CEPH (O), CEF (IV), COL (IV) 
CF3
* 2, 3, 4, 6 7 1 6 AZT (O), COL (N), CEF (IV), COL (IV) 
CF4 2, 3, 4, 6 14 10 4 CEF (IV), COL (IV) 
CF5 2, 3, 4, 6 10 7 3 
 CF6 2, 3, 4, 6 16 9 7 AZT (O), COL (N) 
CF7
* 2, 3, 4, 5
*
, 6 28 11 17 AZT (O), COL (N), CEF (IV), COL (IV), MER (IV), FOS (IV) 
CF8 2, 3, 4, 5, 6 33 8 25 CEPH (O), FOS (IV), MER (IV), CEF (IV) 
CF9 2, 3, 4, 5, 6 25 19 6 AZT (O), COL (N), TOB (N), MER (IV), COL (IV) 
CF10 2, 3, 4, 5
*
, 6 27 10 17 MER (IV), COL (IV) 
Total  188 98 90 
  
Table 1: CF patient sputum contained LES variants that harboured different phage complements. Stable samples were collected during periods 
of relative patient health. Exacerbation samples were collected during periods of reduced lung function and hospitalisation of patients, who 
underwent antibiotic treatment for which data is incomplete.  Antibiotics used during the period of the study are shown (where known): CEPH, 
cephadrine; CEF, ceftazidime; COL, colomycin; FOS, fosfomycin; MER, meropenem; TOB, tobramycin; AZT, azithromycin.  Route of 
administration is indicated in brackets: O, oral; N, nebulised; IV, intravenous (used during exacerbations only). 
* 
Patients CF3 and CF7 died 
before completion of this study. 
 
 
 
